iBio, Inc. IBIO 深 滬
等待開盤 12-12 09:30:00 美东时间
2.42
-0.390
-13.88%
華盛通- 最 高2.90
- 今 開2.73
- 成交量 980.57万股
- 最 低 2.28
- 昨 收 2.81
- 總市值 3997.67万
- 52周最高 6.8908
- 市盈率 靜 --
- 換手率 0.06%
- 52周最低 0.5562
- 委 比 -21.82%
- 總股本 1651.93万
- 歷史最高 17400.00
- 量 比 0.21
- 振 幅 22.06%
- 歷史最低 0.5562
- 每 手 1
- 風險率 1.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多3 Penny Stocks to Watch Now, 12/9/25
iBio Inc. ($IBIO), iRobot ($IRBT), and Webuy Global ($WBUY) are the 3Penn...
12-10 00:17
Why is Biotech Stock iBio Up over 50%?
Shares of Texas-based biotech firm iBio ($IBIO) have climbed as high as 50% ove...
12-09 21:57
Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Society of Hematology (ASH) Annual Meeting 2025 on Tuesday, December 9th at 8:00 AM ET
Senti Bio is set to host a conference call and webcast on Dec 9, 2025, to discuss updated clinical results of their SENTI-202, a next-gen Logic Gated off-the-shelf CAR-NK cell therapy targeting CD33 and/or FLT3-expressing hematologic malignancies like AML and MDS. SENTI-202 features an OR GATE activating CAR, a NOT GATE inhibitory CAR, and calibrated-release IL-15 to enhance targeting precision and therapeutic efficacy.acellular persistence and a...
12-04 13:45
iBio to Participate in the 8th Annual Evercore Healthcare Conference
iBio, Inc. (NASDAQ: IBIO) announced its participation in the 8th Annual Evercore Healthcare Conference from December 2–4, 2025, in Miami. Martin Brenner, DVM, Ph.D., CEO and CSO of iBio, will discuss the company’s next-generation obesity pipeline and present non-human primate data for IBIO-610, a potential first-in-class Activin E antibody, during a fireside chat on December 4 at 8:45 a.m. ET. Felipe Duran, iBio’s CFO, will be available for one-o...
11-24 21:15
Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December
Senti Biosciences reported third-quarter 2025 financial results, highlighting progress in the SENTI-202 clinical trial for AML, with plans to present updated data at the ASH Annual Meeting. The company emphasized advancements in its Logic Gate technology for targeted cancer treatment. Financials showed cash reserves down to $12.2 million, increased R&D expenses, and a net loss of $18.1 million. Senti also engaged in investor outreach activities, ...
11-13 21:30
iBio Q1 EPS $(0.11) Misses $(0.10) Estimate, Sales $100.000K Beat $25.000K Estimate
iBio (AMEX:IBIO) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.10) by 7.84 percent. This is a 76.09 percent increase over losses of $(0.46) per share from the same
11-13 05:42
iBio Regains Nasdaq Compliance with Bid Price Rule
The latest update is out from Ibio ( ($IBIO) ). On November 4, 2025, iBio, Inc....
11-05 05:57
iBio Announces New Preclinical Data From Obese NHP Study Evaluating IBIO-610, Activin E Antibody Candidate Supported By Preclinical Data
Previously reported data showed that in a diet-induced obesity mouse model, IBIO-610 drives fat-selective, GLP-1-synergistic weight loss and prevents weight regain following GLP-1 treatment discontinuationNew non-human
10-30 19:24
Why Did iBio Shares Surge Over 11% In Pre-Market Trading?
iBio shares rose sharply after announcing upcoming presentations on its obesity treatment candidate at two industry conferences.
10-23 16:07
Intelligent Bio Solutions Secures Major UK Contract with Multinational Industrial Service Provider
Intelligent Bio Solutions Inc. (INBS) has secured a major contract with one of the UK's largest industrial service providers, marking a significant UK deployment of its rapid, non-invasive drug testing technology. The customer, a global leader in energy, defense, and industrial sectors, employs over 30,000 staff worldwide and 3,000 within the UK and Ireland. Transitioning from traditional urine-based testing, the company expects faster, cleaner, ...
10-23 12:30
